WO2017196048A1 - Composition à application externe pour soulager les rides de la peau, contenant un extrait de produit de germe de blé fermenté en tant qu'ingrédient actif - Google Patents

Composition à application externe pour soulager les rides de la peau, contenant un extrait de produit de germe de blé fermenté en tant qu'ingrédient actif Download PDF

Info

Publication number
WO2017196048A1
WO2017196048A1 PCT/KR2017/004772 KR2017004772W WO2017196048A1 WO 2017196048 A1 WO2017196048 A1 WO 2017196048A1 KR 2017004772 W KR2017004772 W KR 2017004772W WO 2017196048 A1 WO2017196048 A1 WO 2017196048A1
Authority
WO
WIPO (PCT)
Prior art keywords
wheat germ
extract
composition
preventing
skin wrinkles
Prior art date
Application number
PCT/KR2017/004772
Other languages
English (en)
Korean (ko)
Inventor
양태주
오한나
이지훈
박승원
이상범
조성준
Original Assignee
씨제이제일제당 (주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170056487A external-priority patent/KR101929657B1/ko
Application filed by 씨제이제일제당 (주) filed Critical 씨제이제일제당 (주)
Publication of WO2017196048A1 publication Critical patent/WO2017196048A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present application relates to an external preparation composition for improving skin wrinkles containing an extract of wheat germ fermentation as an active ingredient.
  • skin wrinkles are known to be produced by various factors such as the moisture content of the skin, the content of collagen, and the ability to act on the external environment.
  • collagen is known to have the greatest effect on the formation of skin wrinkles. have.
  • Collagen is mostly present in the dermal layer of the skin and accounts for about 70-80% of the total dry weight of the skin, supporting most of the extracellular matrix.
  • biosynthesis of collagen is reduced by internal factors such as decrease of cellular activity due to natural aging, and the decomposition of collagen is accelerated by the increase of stress caused by harmful environment and external factors such as sun rays, and the skin substrate is destroyed. Wrinkles are created. Therefore, much research has been conducted on active ingredients that can prevent and improve such phenomena.
  • Elastase present in human neutrophil granulocytes is an enzyme that degrades elastin, a substrate protein important for maintaining skin elasticity in the dermis, and also has collagen-degrading activity.
  • elastin When Elastase is properly expressed and activated, it is involved in wound recovery, but when overexpressed or activated, elastin loses elasticity by decomposing elastin in the skin. Therefore, elastase inhibitors have an effect of improving skin wrinkles, and ursolic acid is used as an elastase inhibitor.
  • an external preparation composition for improving skin wrinkles containing Jeonho extract or parsley extract (Korean Patent No. 0507292), an external preparation composition for improving wrinkles containing natural extracts such as rhubarb, sandalwood and sandalwood (Korea Patent No. 1220903)
  • natural products such as external skin composition containing scleroglucan (Korean Patent Publication No. 2010-0043923), as well as an aqueous dispersion of a film-forming polymer composed of polyurethane and acrylic polymer dispersed in water
  • synthetic polymers such as the composition for external preparations for skin (Korean Patent No. 1101363), has also been made.
  • a skin external preparation composition for improving wrinkles derived from natural products that is satisfactory to consumers in terms of stability and wrinkle improvement.
  • the present inventors have made efforts to develop an external composition for improving wrinkles by fermenting natural materials, and as a result, the extract of wheat germ fermentation and 2,6-dimethoxybenzoquinone (2,6-DMBQ: 2,6-Dimethoxybenzoquinone) While excellent in safety, while inhibiting collagen and elastin degradation while increasing collagen biosynthesis, when applied to the skin it was confirmed that the effect of improving skin wrinkles (for example, wrinkles on the eyes) was completed.
  • 2,6-dimethoxybenzoquinone 2,6-dimethoxybenzoquinone
  • Another object of the present invention to provide a quasi-drug composition for preventing or improving skin wrinkles containing the compound of Formula 1, or wheat germ fermentation or extracts thereof.
  • Another object of the present invention is to provide a method of preventing, ameliorating or treating skin wrinkles, comprising administering the compound of Formula 1, or wheat germ fermentation product or extract thereof, or a composition of the present invention to a subject in need thereof. To provide.
  • compositions herein are non-toxic, promote procollagen biosynthesis, inhibit collagenase and elastase expression by ultraviolet light, and have the effect of reducing dermal density and skin wrinkle depth to prevent, improve or It can be used for therapeutic purposes.
  • Figure 2 is a graph showing the results of performing the cytotoxicity test on the NHDF cells of the extract of wheat germ fermentation (CJ) according to an embodiment of the present application.
  • Figure 3 is the result of measuring the cytotoxicity to 2,6-DMBQ human skin fibroblasts.
  • FIG. 4A and 4B are graphs showing the type 1 procollagen biosynthesis of extracts of wheat germ fermentation (FIG. 4A) and 2,6-DMBQ (FIG. 4B) according to an embodiment of the present disclosure.
  • Figures 5a and 5b is a graph comparing the inhibitory activity of MMP-1 production by ultraviolet irradiation of the extract of the wheat germ fermentation (FIG. 5a) and 2,6-DMBQ (Fig. 5b) according to an embodiment of the present application.
  • Figure 6 is a graph comparing the inhibition of the elastase activity of the extract of wheat germ fermentation according to an embodiment of the present application.
  • FIG. 7 is a diagram illustrating wrinkle parameters R1 and R3 in the case of measuring the wrinkles around the eyes.
  • FIG. 8A to 8f is a view comparing the extract containing product (CJD cream) and the negative control product (control cream) of wheat germ fermentation according to an embodiment of the present application.
  • FIG. 8A is a graph showing changes in wrinkles around the eye area of each time point
  • FIG. 8B is a graph illustrating the increase / decrease rate of wrinkles around the eyes according to the use of the product by time point
  • FIG. 8D is a graph showing changes in skin dermal density by time point
  • FIG. 8E is a graph showing increase and decrease of dermal density according to product use at each time point
  • FIG. 8F is a photograph showing changes in dermal density of individuals according to product use. to be.
  • FIG. 9A to 9F are diagrams comparing the extract-containing product (CJD cream) and the positive control product (ADE cream: adenosine containing) of the wheat germ fermentation according to an embodiment of the present application.
  • FIG. 9A is a graph showing changes in wrinkles around the eyes
  • FIG. 9B is a graph illustrating increases and decreases in the wrinkles around the eyes according to the use of products by time
  • FIG. 9C is a photograph illustrating changes in the wrinkles of the eyes according to the use of products.
  • FIG. 9D is a graph showing changes in skin dermal density by time point
  • FIG. 9E is a graph showing increase and decrease of dermal density according to product use at each time point
  • FIG. 9F is a photograph showing changes in dermal density of an individual according to product use. to be.
  • the present application provides a cosmetic composition for preventing or improving skin wrinkles comprising a compound represented by the following formula (1), or wheat germ fermentation or extracts thereof.
  • Compound represented by Formula 1 of the present application is a compound named 2,6-dimethoxybenzoquinone (2,6-DMBQ: 2,6-Dimethoxybenzoquinone), a chemical or biological synthesis, or purchased commercially Can be used. Alternatively, it can be obtained by separating from natural products (eg, plants, etc.) known to contain the compounds of the present application. However, it is not particularly limited thereto. Herein, it was confirmed that the compound represented by Chemical Formula 1 included in the wheat germ fermentation product or its extract has the effect of preventing or improving skin wrinkles.
  • the term "wheat germ” means the seed of wheat. It is a nutritious embryo of wheat kernels (wheat kernel) that is removed from the process of processing whole wheat flour, which takes about 2 to 3% of the whole wheat grain. Wheat germ is known to be rich in vitamin E (tocopherol), which is known to be an antioxidant vitamin to date, and recent studies have shown that natural substances extracted from fermented wheat germ restore the damaged immune function of the human body. However, the effect of improving the wrinkles of wheat germ is not known.
  • vitamin E tocopherol
  • Wheat germs herein may include, but are not limited to, dried, milled, concentrate and mixtures thereof.
  • fixation refers to any activity or process, including enzymatic or metabolic degradation of organic material with microorganisms.
  • the term "wheat embryo fermentation” means the result of enzymatic or metabolic degradation of wheat germ with a microorganism.
  • the wheat germ fermentation herein may comprise a compound of Formula 1 herein.
  • wheat germ fermentation of the present application may be obtained by inoculating microorganisms in wheat germ or a medium containing the same and then cultured.
  • the microorganism may be at least one selected from the group consisting of yeast, lactic acid bacteria, bacteria, and fungi.
  • the yeast is for example Saccharomyces cerevisiae ( Saccharomyces cerevisiae ), Saccharomyces ellipsoideus ( S. ellipsoideus ), Saccharomyces correaus ( S. coreanus ), Saccharomyces Carlsbergensis ( S. carlsbergensis), Saccharomyces access to my Paz Astoria Augustine (S. pastorianus), Saccharomyces access to my lactis (S. lactis), Saccharomyces access to my ruksi (S.
  • yeast may be Saccharomyces cerevisiae.
  • the lactic acid bacteria are for example Bifidobacterium sp.), Lactobacillus sp., Lactococcus sp., Pediococcus sp., Streptococcus. sp, or Leuconostoc sp.) but may be a microorganism, but is not limited thereto so long as it can have an effect of preventing or improving skin wrinkles.
  • the lactic acid bacteria are Bifidobacterium bifidum ( B. bifidum ), Bifidobacterium breve ( B. breve ), Bifidobacterium long gum ( B. longum ), Bifidobacterium animalis ( B.
  • Bifidobacterium lactis B. lactis
  • Lactobacillus ashdophyllus L. acidophilus
  • Lactobacillus casei L. casei
  • Lactobacillus gaseri L. gasseri
  • lactic acid bacteria may be used in the same sense as lactic acid bacteria.
  • the fungus used in the fermentation may include, but is not limited to, mushrooms, for example, shiitake mushrooms, oyster mushrooms, enoki mushrooms, matsutake mushrooms, mushroom mushrooms, tree mushrooms, roe deer mushrooms, It may be a ganoderma lucidum mushroom, or a situation mushroom, but is not limited thereto as long as it can exhibit the effect of preventing or improving skin wrinkles.
  • the inoculation amount, the culture temperature, the culture humidity, and the incubation time of the microorganisms used to prepare the wheat germ fermentation product of the present application may be appropriately selected by those skilled in the art in consideration of the types of microorganisms used for the fermentation.
  • the culture of the present application may be carried out for 12 to 60 hours at a temperature of 20 °C to 40 °C.
  • the culture of the present application is 25 °C to 35 °C, 28 °C to 32 °C or 30 °C temperature and / or 12 hours to 50 hours, 20 hours to 50 hours, 30 hours to 50 hours, 35 hours to 45 hours, 38 It can be carried out for hours to 42 hours or 40 hours.
  • extract of wheat germ fermentation refers to a material that has removed microorganisms from wheat germ fermentation.
  • the extract of the wheat germ fermentation of the present application may be a supernatant obtained by centrifuging the wheat germ fermentation of the present application. More specifically, the centrifugation is revolution per minute of 6,000 rpm to 10,000 rpm, 7000 rpm to 9000 rpm, 7500 rpm to 8500 rpm, 7800 rpm to 8200 rpm or 8000 rpm and / or 5 minutes to 120 minutes.
  • the extract of wheat germ fermentation herein may comprise a compound of Formula 1 herein.
  • Extracts of wheat germ fermentation herein include extracts of all formulations that can be formed using extracts such as extracts of the wheat germ fermentation herein and their dilutions, concentrates, dry matters, crudes, tablets or mixtures thereof.
  • the extract of the wheat germ fermentation of the present application may be a dry matter, more specifically, may be a freeze-dried product.
  • the extract of the wheat germ fermentation of the present application can be obtained from wheat germ fermentation by any method as long as it has an effect of preventing, improving or treating wrinkles.
  • Cold extraction method to extract at room temperature to 25 °C, heat extraction method to be extracted by heating to 40 to 100 °C, ultrasonic extraction method by applying ultrasonic waves, reflux extraction method using a reflux cooler and the like can be used. These methods may be performed alone or in combination of two or more methods.
  • the type of extraction solvent used for the extraction herein is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the extraction solvent of the present application from the group consisting of water, alcohol having 1 to 4 carbon atoms, hexane, ethyl acetate, chloroform, dichloromethane and mixed solvents thereof A solvent selected may be mentioned, and specifically, the extraction solvent of the present application may be hot water.
  • the extract herein may be one comprising a fraction thereof.
  • fraction refers to the result obtained by performing fractionation to separate a particular component or group of components from a mixture comprising a variety of different components.
  • the fractionation method for obtaining a fraction of the present application is not particularly limited and may be performed according to a method conventionally used in the art. Solvent fractionation by treatment of various solvents, ultrafiltration fractionation through passage of ultrafiltration membranes with constant molecular weight cut-off values, and various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) Chromatography), and combinations thereof.
  • fractional solvent used to obtain the fractions herein is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of fractional solvents herein include polar solvents such as water, alcohols; And nonpolar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of one or more.
  • Wheat germ fermentation herein or extract thereof may be used in 0.001% to 10% by weight relative to the total weight of the composition of the present application, specifically 0.01% to 7% by weight, 0.01% to 5% by weight, 0.01% by weight % To 3%, 0.01% to 2%, 0.01% to 1%, 0.05% to 10%, 0.05% to 7%, 0.05% to 5%, 0.05% to 3 wt%, 0.05 wt% to 2 wt%, 0.05 wt% to 1 wt%, 0.1 wt% to 10 wt%, 0.1 wt% to 7 wt%, 0.1 wt% to 5 wt%, 0.1 wt% to 3 wt% %, 0.1 wt% to 2 wt%, 0.1 wt% to 1 wt%, 0.5 wt% to 10 wt%, 0.5 wt% to 7 wt%, 0.5 wt% to 5 wt%, 0.5
  • Wheat germ fermentation herein or extract thereof may be included in the composition of the present application 0.1 ⁇ g / ml to 200 ⁇ g / ml.
  • the wheat germ fermentation product or the extract thereof may be 0.1 ⁇ g / ml to 150 ⁇ g / ml, 0.1 ⁇ g / ml to 100 ⁇ g / ml, 0.1 ⁇ g / ml to 70 ⁇ g / ml, 0.1 ⁇ g / ml To 50 ⁇ g / ml, 0.5 ⁇ g / ml to 200 ⁇ g / ml, 0.5 ⁇ g / ml to 150 ⁇ g / ml, 0.5 ⁇ g / ml to 100 ⁇ g / ml, 0.5 ⁇ g / ml to 70 ⁇ g / ml, 0.5 ⁇ g / ml To 50 ⁇ g / ml, 0.8 ⁇ g / ml to 200
  • the compound represented by Formula 1 of the present application may be used in 0.00001% to 0.1% by weight relative to the total weight of the composition, specifically 0.0001% to 0.07% by weight, 0.0001% to 0.05% by weight, 0.0001% by weight To 0.3 wt%, 0.0001 wt% to 0.02 wt%, 0.0001 wt% to 0.01 wt%, 0.0005 wt% to 0.1 wt%, 0.0005 wt% to 0.07 wt%, 0.0005 wt% to 0.05 wt%, 0.0005 wt% to 0.03 Wt%, 0.0005 wt% to 0.02 wt%, 0.0005 wt% to 0.01 wt%, 0.001 wt% to 0.1 wt%, 0.001 wt% to 0.07 wt%, 0.001 wt% to 0.05 wt%, 0.001 wt% to 0.03 wt% , 0.001 wt% to
  • the compound represented by Formula 1 of the present application may be included in 0.1 ng / ml to 1250 ng / ml in the composition of the present application.
  • wheat germ fermentation herein or extract thereof is 0.1 ng / ml to 1000 ng / ml, 0.1 ng / ml to 500 ng / ml, 0.1 ng / ml to 200 ng / ml, 0.1 ng / ml To 120 ng / ml, 0.1 ng / ml to 90 ng / ml, 0.1 ng / ml to 60 ng / ml, 0.1 ng / ml to 30 ng / ml, 1 ng / ml to 1250 ng / ml, 1 ng / ml To 1000 ng / ml, 1 ng / ml to 500 ng / ml, 1 ng / ml to 200 ng
  • the term “wrinkle” refers to a fine line caused by skin decay and may be caused by a gene, a decrease in collagen present in skin dermis, an external environment, and the like.
  • the wrinkles may include skin aging or skin elasticity reduction.
  • the skin aging refers to the type and intangible changes that appear on the skin with age, as well as endogenous aging (natural aging) that occurs with everyone without special environmental factors, as well as stress, ultraviolet rays, smoking, drug use, etc. It may include all of the exogenous aging that occurs as a cause.
  • Photoaging in the exogenous aging refers to a phenomenon in which skin damage occurs, such as decreased elasticity and moisture of the skin and wrinkles upon repeated or prolonged exposure to ultraviolet rays of sunlight. Specifically, the photoaging may refer to an actinic elastosis symptom that causes degeneration or deposition of elastic fibers, thermal insulation of collagen fibers, and the like.
  • Wrinkles of the present application may be wrinkles that occur on the face, neck, etc. of the eyes, the forehead, forehead, and the like, and specifically, may be wrinkles around the eyes.
  • compositions of the present disclosure may promote procollagen biosynthesis, inhibit collagenase (MMP-1) expression by ultraviolet radiation, inhibit elastase activity and / or increase skin dermal density. have.
  • prevention means any action by which a composition according to the present invention inhibits or delays the occurrence of wrinkles.
  • the term "improvement” means any action that at least reduces the parameters associated with the condition of wrinkles, such as the extent of wrinkles.
  • the improvement herein may be a decrease in the depth of the wrinkles, an increase in the dermal density and / or a decrease in the number of wrinkles in a given area.
  • compositions herein are selected from the group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, sprays and packs It may be formulated in a form that is provided.
  • Cosmetic compositions herein may further comprise a cosmetically acceptable carrier.
  • the kind of the cosmetically acceptable carrier of the present application is not particularly limited as long as it does not impair the activity and properties of the cosmetic composition of the present application, any carriers commonly used in the art and cosmetically acceptable may be used.
  • Non-limiting examples of the cosmetically acceptable carrier include saline, sterile water, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more thereof.
  • the cosmetically acceptable carrier of the present disclosure may include a non-naturally occuring carrier.
  • the cosmetically acceptable carriers herein vary depending on the formulation of the cosmetic composition.
  • the carrier component is animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide and the like. May be used, but is not limited thereto.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. may be used as the carrier component, and in particular, in the case of a spray, additionally chlorofluoro Propellants such as, but not limited to, hydrohydrocarbons, propane / butane or dimethyl ether.
  • a solvent, a solubilizer or an emulsifier may be used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzo
  • a carrier component for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzo
  • propylene glycol, 1,3-butylglycol oil and the like can be used, and in particular, cottonseed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or sorbitan Fatty acid esters may be used, but are not limited thereto.
  • the formulation of the cosmetic composition of the present application is a suspension
  • a liquid diluent such as water, ethanol or propylene glycol
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester
  • Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant may be used, but is not limited thereto.
  • the formulation of the cosmetic composition of the present application is a soap
  • the carrier component alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars and the like It may be used, but is not limited thereto.
  • the formulation of the cosmetic composition of the present application is a pack, a peel-off pack containing polyvinyl alcohol or the like, a wash-off pack containing pigments such as kaolin, talc, zinc oxide, or titanium dioxide in the general emulsion cosmetic It includes all, or the form of the mask sheet pack, but is not particularly limited thereto.
  • the cosmetic composition of the present application may further include components included in conventional skin external preparation components such as water, surfactants, humectants, lower alcohols, chelating agents, fungicides, antioxidants, preservatives, pigments and flavorings.
  • conventional skin external preparation components such as water, surfactants, humectants, lower alcohols, chelating agents, fungicides, antioxidants, preservatives, pigments and flavorings.
  • the present application provides a pharmaceutical composition for preventing or treating skin wrinkles containing a compound of formula (1), or wheat germ fermentation or extract thereof.
  • the compound of Formula 1 wheat germ, fermented wheat germ, extract of wheat germ fermentation, skin wrinkles and prevention are all described above.
  • treatment means any action that causes the composition to improve or benefit from the appearance of skin wrinkles. Specifically, it may be a decrease in the depth of wrinkles, increase in the dermal density, decrease in the number of wrinkles in a certain area and / or removal of wrinkles.
  • the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.
  • the term "pharmaceutically acceptable carrier” refers to a carrier or diluent that does not irritate an organism and does not inhibit the anti-wrinkle or therapeutic activity and properties of the pharmaceutical compositions of the present application.
  • Acceptable pharmaceutical carriers in compositions formulated as liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol And one or more of these components may be used in combination, and other conventional additives such as antioxidants, buffers, bacteriostatic agents may be added as necessary.
  • the pharmaceutically acceptable carrier herein may include an unnatural carrier.
  • compositions herein may be administered in single or multiple amounts in pharmaceutically effective amounts.
  • the term “pharmaceutically effective amount” means an amount sufficient to prevent or treat a disease at a reasonable benefit / risk ratio applicable to medical prophylaxis or treatment, and an effective dose level refers to the severity of the disease, the activity of the drug. , Factors including the body weight, health, sex of the patient, sensitivity to the drug of the patient, time of administration of the composition used herein, route of administration and rate of release, duration of treatment, drugs used in combination with or concurrently with the composition of the invention used and others It may be determined according to factors well known in the medical field.
  • the term "administration" means introducing a given substance into a subject in any suitable manner and can be administered via any general route by which the compositions herein can reach a target in vivo.
  • the route of administration of the compositions herein is not particularly limited but may be oral or parenteral. Specifically, it may be administered parenterally, and more specifically, it may be applied in a manner of applying to the skin (ie, transdermal administration). Specifically, the administration of the present application may be performed once to four times, two to three times or twice a day. In addition, the administration herein may be carried out for a period of at least 4 weeks, at least 8 weeks, 4 to 12 weeks or 8 to 12 weeks.
  • the present application provides a quasi-drug composition for preventing or improving skin wrinkles containing a compound of Formula 1, or wheat germ fermentation or extract thereof.
  • the term "quasi drug” refers to articles that are less effective than drugs among those used for the purpose of diagnosing, treating, ameliorating, alleviating, treating, or preventing a disease in humans or animals.
  • the drug is used for the purpose of medicine, and it includes a product used for the treatment or prevention of diseases of humans and animals, and a product having a slight or no direct action on the human body.
  • the quasi-drug composition of the present application may be prepared in a form selected from the group consisting of body cleanser, foam, soap, mask, ointment, cream, lotion, essence and spray, but is not limited thereto.
  • the extract of the compound of formula 1, wheat germ fermentation or wheat germ fermentation herein is used as a quasi-drug additive
  • the extract of the compound of formula 1, wheat germ fermentation or wheat germ fermentation of the present application is added as is or other quasi-drug or quasi-drug components It can be used together, and can be suitably used according to a conventional method.
  • skin wrinkles comprising administering a compound of formula (1), wheat germ fermentation or extract thereof, or a composition of the present invention to a subject in need thereof Provide a method of preventing, ameliorating or treating.
  • the compound of formula 1 wheat germ, fermentation of wheat germ, extract of wheat germ fermentation, skin wrinkle, prevention, improvement, treatment and administration of the present invention are described above. One bar applies to all.
  • wheat germ 50 g of wheat germ (CJ CheilJedang) and 500 g of water were added to the flask, mixed well, and sterilized at 121 ° C. for 15 minutes and cooled. Then, 5% (2.5 g) of dry yeast [bread yeast (Saccharomyces cerevisiae), Angel Yeast] was inoculated, fermented at 30 ° C. for 40 hours, and then 20 minutes at 8000 rpm. The supernatant was taken by centrifugation. The supernatant was lyophilized and recovered to prepare an extract of wheat germ fermentation.
  • dry yeast bread yeast (Saccharomyces cerevisiae), Angel Yeast
  • the extract of the wheat germ fermentation was named 'CJ'.
  • NHDF cells were dispensed in 96-well plates at 6 ⁇ 10 3 cells / well, followed by Fibroblast Basal Medium, FBM containing 0.1% Insulin, 0.1% rhFGF, 0.1% gentamicin, 2% FBS. Lonza, CC-3131) medium and maintained at 37 °C incubated for 24 hours in an incubator containing 5% carbon dioxide. After incubation for 12 hours, after starvation, the fermented wheat germ extract of Experimental Example 1 and the FBM medium without the supplement (supplement), respectively, were added and cultured for 24 hours. .
  • the WST-1 water-soluble tetrazolium salt-1, Roche
  • the absorbance at 450 nm was measured.
  • the relative cell viability of the case where the NHDF cells were treated with only the FBM medium except for the sample (control), when the extract (CJ) of the wheat germ fermented product of Preparation Example 1 (test) was expressed as a percentage.
  • the concentration of the sample was set to 50 ⁇ g / ml or less.
  • HDF human dermal fibroblasts
  • 2,6-DMBQ Sigma-Aldrich
  • cytotoxicity of human dermal fibroblasts (HDF) of 2,6-DMBQ was measured.
  • HDF cells were cultured in DMEM with 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin added to 6 ⁇ 10 5 cells / well.
  • FBS fetal bovine serum
  • penicillin / streptomycin added to 6 ⁇ 10 5 cells / well.
  • the cells were cultured in a 5% CO 2 incubator using a 100 mm cell culture dish, and the cells that reached confluence were kept passaged using Trypsin-EDTA.
  • DMEM serum free, P / S 1%) medium containing 10% of EZ-CYTOX (EZ-1000, Daeil lab service, Korea), and the absorbance was measured at 450 nm using a plate reader. The cell viability was determined.
  • NHDF cells were aliquoted into 1 ⁇ 10 4 cells / well in 48-well plates and incubated for 24 hours in the same FBM medium as in Experimental Example 1. Thereafter, the medium was removed, and the cells were starved for 24 hours, and then the extracts of wheat germ fermentation of Preparation Example 1 and 2,6-DMBQ were diluted in FBM (except additives), respectively, by concentration (wheat flour fermented product). Extracts: 1 ⁇ g / ml, 10 ⁇ g / ml, 50 ⁇ g / ml; 2,6-DMBQ: 15 ng / ml, 30 ng / ml, 60 ng / ml and 120 ng / ml) Time incubation.
  • procollagen type I c-peptide (PIP) EIA kit TAKARA, MK101
  • PIP procollagen type I c-peptide
  • NHDF cells were dispensed into 24-well plates at 2 ⁇ 10 4 cells / well and then incubated for 24 hours in the same medium as Experimental Example 1. After 24 hours, the medium was discarded and washed with DPBS, and then UV-B 40 mJ / cm 2 was irradiated by adding 200 ⁇ l of DPBS. Thereafter, the extracts (CJ) of the wheat germ fermentation product of Preparation Example 1, the same concentrations as in Experimental Example 2-1, were treated to the cells and incubated for 24 hours. Subsequently, the culture medium was taken and the amount of MMP-1 was measured by a human whole MMP-1 ELISA kit (R & D system, DY901), and the measured amount of MMP-1 was corrected by the total protein amount.
  • CJ extracts of the wheat germ fermentation product of Preparation Example 1
  • the MMP-1 amount was measured in the same manner except that UV-B irradiation was performed at 15 mJ / cm 2 , and retinoic acid was used as a positive control.
  • composition (% by weight) disclosed in Table 4 a cosmetic cream containing an extract of wheat germ fermentation of Preparation Example 1 as an active ingredient was prepared according to a conventional method.
  • 'CJD cream' Wrinkle improvement effect of the cosmetic cream prepared in Example 1-1 (hereinafter referred to as 'CJD cream'), a negative control (cream containing the same amount of purified water instead of the extract of wheat germ fermentation in the composition of Table 4, below) Clinical evaluation by comparing with a control cream) or a positive control (a cream containing 0.04% of adenosine, an ingredient for wrinkle improvement functional notification, instead of an extract of wheat germ fermentation, hereinafter referred to as an ADE cream) was performed.
  • the subjects were 20 Korean females aged 30-55 years who had eye wrinkles (Gross Hearing Skin Care Center SOP 3).
  • control cream and the area to be applied with the ADE cream and the CJD cream are allocated through block randomization and used for 12 weeks, and then before use (0 week), after 4 weeks, after 8 weeks, and after 12 weeks.
  • visual evaluation, instrumental measurements (photographing, skin wrinkles, dermal density) and safety evaluation were performed to evaluate the effectiveness of the cream containing the extract of wheat germ fermentation on the improvement of wrinkles of human skin. Specific sample information and method of use are summarized in Table 5 and Table 6 below.
  • the instrument was measured for dermal density of right and left cheeks of clinical evaluation chiefs before and after 4 weeks of use, 4 weeks, 8 weeks, and 12 weeks of use. It was.
  • Skin-Visiometer® SV600 (Courage + Khazaka GmbH, Germany) is a device that measures the improvement of skin wrinkles by analyzing the intensity of light generated by the light emitted from an artificial light source passing through a silicon material. It was put into an analysis kit and analyzed by Imagemeter software of Visiometer. As R1 and R3 values decrease, skin wrinkles are improved and depth of wrinkles is lowered.
  • the unit is an arbitrary unit (AU).
  • the wrinkle parameter (R-parameter) R1 represents the distance between the highest point and the lowest point of the profile in terms of skin roughness
  • R3 represents the profile in average roughness. Is successively averaged into five lengths, and then the arithmetic average of the R1 values in each region.
  • CJD cream showed statistically significant decrease in R1 and R3 compared to before use at all time points (after 4 weeks, 8 weeks, and 12 weeks) after using the product. Appeared excellent.
  • DermaScanC®USB is a high-resolution 20MHz ultrasound imaging device that uses ultrasound waves to reflect echoes of different densities to produce echoes of varying sizes, allowing imaging of changes in the skin and dermal layer changes due to collagen fiber reflectance.
  • the magnitude of the echo is synthesized by the computer and expressed in color to create a two-dimensional image.
  • the subjects measured the dermal density of the left and right cheeks (the area where the tip of the nose and the side of the nose meet) using DermaScanC®USB. Density values were analyzed in the captured images.
  • the CJD cream use group had a statistically significant increase (improvement) in the dermis density at 12 weeks after product use (Table 10 and FIGS. 8D-8F).
  • the results of the evaluation were analyzed statistically using SPSS® Package Program version 22.
  • the normality of the measured values before using the test product was tested by the Sapiro-wilks test. Comparisons before and after use of the product are performed using the Repeated Measures ANOVA if the measured values meet the normal distribution, and the nonparametric methods (Krusckal-Wallis and Mann-Whitney U test) if the measured values do not meet the normal distribution. Significance was verified.
  • the comparison between groups was performed using Repeated Measures ANOVA in consideration of the interdependence (interaction) of the results that were repeatedly measured in the same subject, and the significance level was set to p ⁇ 0.05. .
  • Survey evaluation was analyzed using frequency analysis.
  • CJD cream showed a significant wrinkle improvement effect compared to the control cream.
  • the change of R-parameters according to the time points between the groups is shown in Table 14, and the wheat germ fermentation extract is a natural extract, but the adenosine containing ADE obtained through chemical purification process (resin adsorption, ammonia, ethanol elution, etc.) after microbial fermentation It was found to have the same level of effect as the cream.
  • the CJD cream showed a statistically significant increase (improvement) in the thickness of the dermis at 12 weeks after the use of the product, and an increase in the density at 8 and 12 weeks after the use of the product (p ⁇ 0.05) (Table ⁇ 15 and FIGS. 9D-9F). This improvement was similar or higher than that of ADE cream.
  • the skin dermal density change of each time point between the groups is shown in Table 16.
  • the wheat germ fermentation extract is a natural extract but has an equivalent effect to the ADE cream containing adenosine, which has undergone chemical purification.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition à application externe pour prévenir, soulager ou traiter des rides de la peau contenant, comme ingrédient actif, un composé de formule chimique 1 ou un produit de germe de blé fermenté ou un extrait de celui-ci.
PCT/KR2017/004772 2016-05-11 2017-05-08 Composition à application externe pour soulager les rides de la peau, contenant un extrait de produit de germe de blé fermenté en tant qu'ingrédient actif WO2017196048A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2016-0057778 2016-05-11
KR20160057778 2016-05-11
KR1020170056487A KR101929657B1 (ko) 2016-05-11 2017-05-02 밀배아 발효물의 추출물을 유효성분으로 함유하는 피부 주름 개선 외용제 조성물
KR10-2017-0056487 2017-05-02

Publications (1)

Publication Number Publication Date
WO2017196048A1 true WO2017196048A1 (fr) 2017-11-16

Family

ID=60267113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/004772 WO2017196048A1 (fr) 2016-05-11 2017-05-08 Composition à application externe pour soulager les rides de la peau, contenant un extrait de produit de germe de blé fermenté en tant qu'ingrédient actif

Country Status (1)

Country Link
WO (1) WO2017196048A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02154662A (ja) * 1988-12-05 1990-06-14 Kiyourin Yobou Igaku Kenkyusho:Kk 活性酸素抑制組成物
US20050089499A1 (en) * 2002-01-15 2005-04-28 Philippe Moussou Active substances for use in cosmetic and/or pharmaceutical products, obtainable from the fermentation of plant components and/or plant extracts
KR20050059066A (ko) * 2002-08-09 2005-06-17 마테 히드베기 발효된 밀 배 추출물의 항염증제로서의 용도
JP2009234943A (ja) * 2008-03-26 2009-10-15 Toyobo Co Ltd 植物抽出物を含有する化粧品組成物
CN104222287A (zh) * 2014-10-15 2014-12-24 张德信 一种能抗疲劳防衰老的保健牛奶及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02154662A (ja) * 1988-12-05 1990-06-14 Kiyourin Yobou Igaku Kenkyusho:Kk 活性酸素抑制組成物
US20050089499A1 (en) * 2002-01-15 2005-04-28 Philippe Moussou Active substances for use in cosmetic and/or pharmaceutical products, obtainable from the fermentation of plant components and/or plant extracts
KR20050059066A (ko) * 2002-08-09 2005-06-17 마테 히드베기 발효된 밀 배 추출물의 항염증제로서의 용도
JP2009234943A (ja) * 2008-03-26 2009-10-15 Toyobo Co Ltd 植物抽出物を含有する化粧品組成物
CN104222287A (zh) * 2014-10-15 2014-12-24 张德信 一种能抗疲劳防衰老的保健牛奶及其制备方法

Similar Documents

Publication Publication Date Title
WO2021107706A1 (fr) Nouvelle utilisation d'exosomes du lait
WO2016047907A1 (fr) Composition contenant des cellules mortes de lactobacillus tyndalisé comme ingrédient actif pour hydrater la peau ou atténuer les rides
WO2019226003A1 (fr) Souche de lactobacillus gasseri kbl697 et son utilisation
WO2018174369A1 (fr) Produit de colostrum fermenté par des bactéries lactiques et composition cosmétique l'utilisant
WO2020218781A1 (fr) Composition fonctionnelle contenant un milieu de culture riche en exosomes dérivé d'une cellule souche immortalisée et un extrait de bourgeon de rose en tant que principes actifs
WO2018056600A1 (fr) Composition topique pour apaiser la peau, contenant comme principe actif un extrait de germe de blé fermenté
WO2022145663A1 (fr) Composition cosmétique comprenant une masse de bactéries lactiques lactobacillus plantarum mortes ou une culture de bactéries lactiques destinée à prévenir ou à atténuer le vieillissement de la peau
WO2014193014A1 (fr) Bactéries lactiques de taille nanométrique issues du kimchi
WO2019226002A1 (fr) Souche de lactobacillus crispatus kbl693 et utilisation associée
WO2017222317A1 (fr) Composition ayant pour effet d'améliorer l'hydratation de la peau, d'éliminer la kératine cutanée, d'améliorer l'élasticité de la peau, d'inhiber l'érythème, d'atténuer les rides cutanées ou d'atténuer le photovieillissement cutané, contenant une ionone ou un sel de celle-ci comme ingrédient actif
WO2020246766A1 (fr) Composition pour prévenir ou atténuer le vieillissement cutané, contenant un extrait de rhodiola sachalinensis fermenté à l'aide de bovista plumbea
WO2017135556A1 (fr) Composition contenant du gdf11 et son utilisation
KR101929657B1 (ko) 밀배아 발효물의 추출물을 유효성분으로 함유하는 피부 주름 개선 외용제 조성물
WO2018164369A1 (fr) Composition pour améliorer les rides de la peau, contenant un extrait d'hibiscus syriacus traité par une enzyme en tant que principe actif
TW201808324A (zh) 用於皮膚美白之包含經醱酵之小麥胚芽的皮膚外用劑
WO2024181725A1 (fr) Centella asiatica rouge fermenté avec monascus et son utilisation
WO2022260454A1 (fr) Composition pour le traitement de la dermatite atopique ou le renforcement de la barrière cutanée ou la prévention du vieillissement de la peau, comprenant un extrait de forsythia velutina nakai
WO2018117725A1 (fr) Composition pour prévenir la chute des cheveux et favoriser la pousse des cheveux, comprenant des produits animaux marins fermentés
WO2018111042A2 (fr) Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif
WO2019059668A2 (fr) Composition pour la peau contenant, en tant que principe actif, de la crème de lait liquide fermentée par des bactéries lactiques
WO2024071736A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, contenant des cellules mortes de streptococcus pyogenes ou une protéine spea
WO2017014597A1 (fr) Composition cosmétique permettant d'améliorer le blanchissement de la peau contenant un extrait de graines de schisandra chinensis
WO2017142265A1 (fr) Composition contenant de l'acide adipique utilisé comme principe actif pour l'atténuation des rides de la peau et l'amélioration de l'élasticité de la peau
WO2020138834A1 (fr) Composition pour la prévention ou le traitement de maladies de la peau comprenant de la spirée couronne de mariée
WO2017196048A1 (fr) Composition à application externe pour soulager les rides de la peau, contenant un extrait de produit de germe de blé fermenté en tant qu'ingrédient actif

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17796348

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19/03/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17796348

Country of ref document: EP

Kind code of ref document: A1